businessbriefs
11:20in productionCh. 1 · Origin: Not founded, but fused/ 11:20 · ceiling 15 min
Companies

Novartis

1996

A merger born of necessity, not vision — Novartis was built to survive, not invent.

Novartis is a Swiss multinational pharmaceutical corporation formed in 1996 by the merger of Ciba-Geigy and Sandoz. It operates as a publicly traded holding company with two main divisions — Innovative Medicines and Sandoz — and manufactures numerous branded drugs including clozapine, valsartan, imatinib mesylate, and cyclosporine. The merger combined the pharmaceutical and agrochemical divisions of the predecessor firms into an independent entity, and the company has since undergone extensive restructuring, acquisitions, divestitures, and spin-offs — including Alcon (spun off in 2019) and Sandoz (spun off in October 2023).

CompaniesMedicinePhotographyChemistryMedicine across the network →
Chapters & takeaways6
  1. 1:07
    Origin: Not founded, but fused

    Novartis began as a merger — not a startup — and launched operations on 20 December 1996.

  2. 2:09
    Structure: Two engines, one roof

    It was structured from day one as a holding company with two divisions: Innovative Medicines and Sandoz.

  3. 3:25
    Portfolio: Legacy molecules, not moonshots

    Its revenue came from manufacturing and marketing established drugs — clozapine, valsartan, imatinib mesylate — not from early-stage discovery.

  4. 4:28
    Ownership: A parent, not a factory floor

    As a publicly traded Swiss holding company, Novartis owned subsidiaries globally — but did not operate them directly.

  5. 6:25
    Scale: Measured in revenue, not patents

    By 2024 it ranked eighth largest by revenue — proof of scale, not of innovation velocity.

  6. 7:51
    Focus: Carved out, not chosen

    The merger excluded non-pharma units — agrochemicals were spun off or sold, narrowing focus before it even began.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • scale
  • portfolio discipline
  • structural clarity
What does not
  • startups
  • founders
  • venture capital
  • disruption
Study it if
  • corporate strategists
  • pharma analysts
  • M&A historians
Skip it if
  • startup founders
  • VC investors
  • biotech innovators
The written brief1 min read

What the company or idea is

Novartis is a Swiss multinational pharmaceutical corporation formed in March 1996 by the merger of Ciba-Geigy and Sandoz, headquartered in Basel.

How it actually makes money

Novartis makes money by selling branded prescription drugs — including valsartan, imatinib mesylate, and cyclosporine — through its Innovative Medicines division, and generic medicines through its Sandoz division.

What works

The split into two divisions — Innovative Medicines and Sandoz — created internal clarity: one focused on high-margin patented drugs, the other on low-margin, high-volume generics. This structure endured until Sandoz’s spin-off in October 2023.

What does not

The 1996 merger did not create a unified R&D engine. It combined two legacy portfolios without resolving cultural or operational friction between former Ciba-Geigy and Sandoz units — a gap exposed by later divestitures like Alcon (2019) and Sandoz (2023).

What to take from it

The 1996 merger was a defensive consolidation — not a bet on new science — designed to create scale in a consolidating global pharma market. Its longevity reflects execution in portfolio management, not invention.

Is it worth your time

Yes — if you are studying how large pharmaceutical firms restructure over decades, spin off units, and separate innovation from generics; no — if you expect insight into startup dynamics, venture capital, or founder-led disruption.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

NTPC Limited

1975 · 10:19

State ownership doesn’t mean inefficiency — it means control over scale, timing, and plant utilisation.

Play nextBack to Companies
10:19